These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 17438526

  • 21. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma.
    Zhu C, Qin YR, Xie D, Chua DT, Fung JM, Chen L, Fu L, Hu L, Guan XY.
    Oncogene; 2009 Aug 06; 28(31):2821-8. PubMed ID: 19525977
    [Abstract] [Full Text] [Related]

  • 22. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation.
    Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H, Mitsufuji S, Hosoda F, Hirohashi S, Ohki M, Inazawa J.
    Oncogene; 2005 Dec 01; 24(54):8051-60. PubMed ID: 16103878
    [Abstract] [Full Text] [Related]

  • 23. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
    Sugiura H, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, Ogawa R, Katada T, Harata K, Fujii Y.
    Oncol Rep; 2008 Mar 01; 19(3):713-9. PubMed ID: 18288406
    [Abstract] [Full Text] [Related]

  • 24. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
    Ling ZQ, Li P, Ge MH, Zhao X, Hu FJ, Fang XH, Dong ZM, Mao WM.
    Int J Mol Med; 2011 May 01; 27(5):625-35. PubMed ID: 21373750
    [Abstract] [Full Text] [Related]

  • 25. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
    Ito S, Ohga T, Saeki H, Watanabe M, Kakeji Y, Morita M, Yamada T, Maehara Y.
    Anticancer Res; 2007 May 01; 27(5A):3345-53. PubMed ID: 17970080
    [Abstract] [Full Text] [Related]

  • 26. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma.
    Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, Sidransky D.
    Cancer Res; 2005 Jun 01; 65(11):4963-8. PubMed ID: 15930319
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma.
    Kong KL, Kwong DL, Fu L, Chan TH, Chen L, Liu H, Li Y, Zhu YH, Bi J, Qin YR, Law SY, Guan XY.
    Cancer Res; 2010 Nov 01; 70(21):8832-41. PubMed ID: 20978196
    [Abstract] [Full Text] [Related]

  • 29. Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma.
    Fukuoka T, Hibi K, Nakao A.
    Anticancer Res; 2006 Nov 01; 26(5A):3333-5. PubMed ID: 17094449
    [Abstract] [Full Text] [Related]

  • 30. Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer.
    Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K, Matsunaga A, Komuro K, Kanai M, Kawakami A, Fujiwara Y, Kobayashi N, Shirata K, Nishimura N, Okushiba S, Kondo S, Hamada J, Yoshiki T, Moriuchi T, Katoh H.
    Clin Cancer Res; 2004 Jun 01; 10(11):3629-38. PubMed ID: 15173069
    [Abstract] [Full Text] [Related]

  • 31. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
    Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S, Kitajima Y, Takeuchi M, Nakayama M, Oshimura M, Miyazaki K, Joh K, Mukai T.
    Oncogene; 2004 May 27; 23(25):4380-8. PubMed ID: 15007390
    [Abstract] [Full Text] [Related]

  • 32. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM.
    Clin Cancer Res; 2003 Apr 27; 9(4):1441-5. PubMed ID: 12684417
    [Abstract] [Full Text] [Related]

  • 33. [Correlation of aberrant methylation of MGMT gene to MTHFR C677T genetic polymorphisms in esophageal squamous cell carcinoma].
    Xue HC, Wang JM, Xu B, Guo GP, Hua ZL, Zhou Q, Zhu ZH, Ma ZK, Gao J.
    Ai Zheng; 2008 Dec 27; 27(12):1256-62. PubMed ID: 19079989
    [Abstract] [Full Text] [Related]

  • 34. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.
    Mol Cancer; 2008 Nov 06; 7():83. PubMed ID: 18990230
    [Abstract] [Full Text] [Related]

  • 35. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer.
    Takada H, Wakabayashi N, Dohi O, Yasui K, Sakakura C, Mitsufuji S, Taniwaki M, Yoshikawa T.
    Cancer Genet Cytogenet; 2010 Feb 06; 197(1):16-24. PubMed ID: 20113832
    [Abstract] [Full Text] [Related]

  • 36. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
    Sakai M, Kato H, Sano A, Tanaka N, Inose T, Kimura H, Sohda M, Nakajima M, Kuwano H.
    Ann Surg Oncol; 2009 Sep 06; 16(9):2494-501. PubMed ID: 19526206
    [Abstract] [Full Text] [Related]

  • 37. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
    Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q.
    Oncogene; 2007 Feb 08; 26(6):934-44. PubMed ID: 16862168
    [Abstract] [Full Text] [Related]

  • 38. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
    Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E, Inazawa J.
    Carcinogenesis; 2009 Jul 08; 30(7):1139-46. PubMed ID: 19423649
    [Abstract] [Full Text] [Related]

  • 39. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer.
    Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, Osada M, Hoque MO, Upadhyay S, Mori M, Moon C, Sidransky D.
    Cancer Res; 2006 Apr 01; 66(7):3409-18. PubMed ID: 16585162
    [Abstract] [Full Text] [Related]

  • 40. Transforming capacity of two novel genes JS-1 and JS-2 located in chromosome 5p and their overexpression in human esophageal squamous cell carcinoma.
    Fatima S, Chui CH, Tang WK, Hui KS, Au HW, Li WY, Wong MM, Cheung F, Tsao SW, Lam KY, Beh PS, Wong J, Law S, Srivastava G, Ho KP, Chan AS, Tang JC.
    Int J Mol Med; 2006 Jan 01; 17(1):159-70. PubMed ID: 16328025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.